Unity Depreciation vs Free Cash Flow Analysis

UBX Stock

USD 2.25 0.10 4.65%

Unity Biotechnology financial indicator trend analysis is much more than just breaking down Unity Biotechnology prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Unity Biotechnology is a good investment. Please check the relationship between Unity Biotechnology Depreciation and its Free Cash Flow accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unity Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Unity Stock please use our How to Invest in Unity Biotechnology guide.

Depreciation vs Free Cash Flow

Depreciation vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Unity Biotechnology Depreciation account and Free Cash Flow. At this time, the significance of the direction appears to have pay attention.

The correlation between Unity Biotechnology's Depreciation and Free Cash Flow is -0.92. Overlapping area represents the amount of variation of Depreciation that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of Unity Biotechnology, assuming nothing else is changed. The correlation between historical values of Unity Biotechnology's Depreciation and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation of Unity Biotechnology are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Depreciation i.e., Unity Biotechnology's Depreciation and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.92

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Depreciation

Depreciation indicates how much of Unity Biotechnology value has been used up. For tax purposes Unity Biotechnology can deduct the cost of the tangible assets it purchases as business expenses. However, Unity Biotechnology must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Most indicators from Unity Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Unity Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unity Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Unity Stock please use our How to Invest in Unity Biotechnology guide.Sales General And Administrative To Revenue is likely to rise to 83.88 in 2025, whereas Selling General Administrative is likely to drop slightly above 18.9 M in 2025.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	57.8M	25.0M	28.7M	27.3M
Cost Of Revenue	2.2M	19.7M	17.7M	14.1M

Total Operating Expenses Cost Of Revenue

Unity Biotechnology fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets	Common Stock
Total Assets		0.87	0.66	0.69	0.35	0.55	0.28	0.28	-0.01	0.8	-0.31	0.37	0.61	0.63	0.84	0.77	-0.26	-0.35	0.14	0.06	0.05	-0.3	-0.08	0.21	0.89	0.6
Other Current Liab	0.87		0.73	0.87	0.5	0.7	0.34	0.4	-0.18	0.95	-0.51	0.39	0.73	0.76	0.75	0.84	-0.08	-0.62	0.3	-0.27	0.29	-0.59	0.18	0.49	0.74	0.73
Total Current Liabilities	0.66	0.73		0.85	-0.01	0.83	0.77	0.81	-0.72	0.72	-0.79	0.73	0.22	0.44	0.28	0.52	0.46	-0.79	0.78	-0.46	0.73	-0.74	0.65	0.76	0.36	0.74
Total Stockholder Equity	0.69	0.87	0.85		0.15	0.78	0.56	0.74	-0.51	0.89	-0.86	0.57	0.53	0.53	0.44	0.76	0.3	-0.91	0.59	-0.54	0.6	-0.89	0.46	0.81	0.47	0.77
Other Liab	0.35	0.5	-0.01	0.15		0.03	-0.39	-0.44	0.45	0.54	0.26	-0.34	0.61	0.77	0.55	0.47	-0.46	0.03	-0.36	-0.03	-0.33	0.04	-0.37	-0.2	0.53	0.09
Net Tangible Assets	0.55	0.7	0.83	0.78	0.03		0.65	0.68	-0.7	0.73	-0.69	0.59	0.47	0.44	0.26	0.53	0.57	-0.72	0.81	-0.36	0.7	-0.69	0.62	0.74	0.32	0.66
Property Plant And Equipment Net	0.28	0.34	0.77	0.56	-0.39	0.65		0.9	-0.87	0.29	-0.73	0.97	-0.08	0.23	-0.2	0.32	0.62	-0.61	0.85	-0.17	0.89	-0.57	0.82	0.76	-0.18	0.68
Net Debt	0.28	0.4	0.81	0.74	-0.44	0.68	0.9		-0.89	0.4	-0.94	0.87	-0.03	0.12	-0.16	0.36	0.69	-0.84	0.87	-0.46	0.91	-0.82	0.81	0.9	-0.12	0.65
Retained Earnings	-0.01	-0.18	-0.72	-0.51	0.45	-0.7	-0.87	-0.89		-0.23	0.78	-0.76	0.16	-0.03	0.41	-0.08	-0.9	0.7	-0.98	0.47	-0.96	0.69	-0.94	-0.82	0.35	-0.5
Accounts Payable	0.8	0.95	0.72	0.89	0.54	0.73	0.29	0.4	-0.23		-0.56	0.33	0.78	0.77	0.64	0.84	0.07	-0.71	0.36	-0.38	0.31	-0.68	0.18	0.54	0.7	0.71
Cash	-0.31	-0.51	-0.79	-0.86	0.26	-0.69	-0.73	-0.94	0.78	-0.56		-0.71	-0.14	-0.2	0.04	-0.47	-0.64	0.96	-0.79	0.64	-0.84	0.95	-0.72	-0.95	0.0	-0.64
Non Current Assets Total	0.37	0.39	0.73	0.57	-0.34	0.59	0.97	0.87	-0.76	0.33	-0.71		0.04	0.33	-0.13	0.47	0.51	-0.58	0.75	-0.02	0.8	-0.54	0.66	0.7	-0.1	0.72
Non Currrent Assets Other	0.61	0.73	0.22	0.53	0.61	0.47	-0.08	-0.03	0.16	0.78	-0.14	0.04		0.7	0.61	0.77	-0.18	-0.31	0.0	0.02	-0.08	-0.31	-0.21	0.17	0.64	0.56
Other Assets	0.63	0.76	0.44	0.53	0.77	0.44	0.23	0.12	-0.03	0.77	-0.2	0.33	0.7		0.5	0.84	-0.13	-0.33	0.11	0.03	0.15	-0.3	-0.01	0.23	0.51	0.56
Cash And Short Term Investments	0.84	0.75	0.28	0.44	0.55	0.26	-0.2	-0.16	0.41	0.64	0.04	-0.13	0.61	0.5		0.59	-0.62	-0.06	-0.29	0.09	-0.33	-0.02	-0.4	-0.11	0.95	0.23
Common Stock Total Equity	0.77	0.84	0.52	0.76	0.47	0.53	0.32	0.36	-0.08	0.84	-0.47	0.47	0.77	0.84	0.59		-0.1	-0.53	0.17	0.01	0.22	-0.51	-0.01	0.43	0.59	0.66
Common Stock Shares Outstanding	-0.26	-0.08	0.46	0.3	-0.46	0.57	0.62	0.69	-0.9	0.07	-0.64	0.51	-0.18	-0.13	-0.62	-0.1		-0.59	0.89	-0.5	0.82	-0.6	0.81	0.71	-0.5	0.27
Non Current Liabilities Total	-0.35	-0.62	-0.79	-0.91	0.03	-0.72	-0.61	-0.84	0.7	-0.71	0.96	-0.58	-0.31	-0.33	-0.06	-0.53	-0.59		-0.74	0.75	-0.77	1.0	-0.67	-0.93	-0.11	-0.68
Capital Surpluse	0.14	0.3	0.78	0.59	-0.36	0.81	0.85	0.87	-0.98	0.36	-0.79	0.75	0.0	0.11	-0.29	0.17	0.89	-0.74		-0.48	0.94	-0.72	0.91	0.85	-0.2	0.59
Other Current Assets	0.06	-0.27	-0.46	-0.54	-0.03	-0.36	-0.17	-0.46	0.47	-0.38	0.64	-0.02	0.02	0.03	0.09	0.01	-0.5	0.75	-0.48		-0.5	0.76	-0.57	-0.64	0.06	-0.22
Other Stockholder Equity	0.05	0.29	0.73	0.6	-0.33	0.7	0.89	0.91	-0.96	0.31	-0.84	0.8	-0.08	0.15	-0.33	0.22	0.82	-0.77	0.94	-0.5		-0.76	0.96	0.91	-0.33	0.56
Total Liab	-0.3	-0.59	-0.74	-0.89	0.04	-0.69	-0.57	-0.82	0.69	-0.68	0.95	-0.54	-0.31	-0.3	-0.02	-0.51	-0.6	1.0	-0.72	0.76	-0.76		-0.66	-0.93	-0.07	-0.66
Property Plant And Equipment Gross	-0.08	0.18	0.65	0.46	-0.37	0.62	0.82	0.81	-0.94	0.18	-0.72	0.66	-0.21	-0.01	-0.4	-0.01	0.81	-0.67	0.91	-0.57	0.96	-0.66		0.82	-0.41	0.48
Preferred Stock Total Equity	0.21	0.49	0.76	0.81	-0.2	0.74	0.76	0.9	-0.82	0.54	-0.95	0.7	0.17	0.23	-0.11	0.43	0.71	-0.93	0.85	-0.64	0.91	-0.93	0.82		-0.11	0.66
Total Current Assets	0.89	0.74	0.36	0.47	0.53	0.32	-0.18	-0.12	0.35	0.7	0.0	-0.1	0.64	0.51	0.95	0.59	-0.5	-0.11	-0.2	0.06	-0.33	-0.07	-0.41	-0.11		0.3
Common Stock	0.6	0.73	0.74	0.77	0.09	0.66	0.68	0.65	-0.5	0.71	-0.64	0.72	0.56	0.56	0.23	0.66	0.27	-0.68	0.59	-0.22	0.56	-0.66	0.48	0.66	0.3

Click cells to compare fundamentals

Unity Biotechnology Account Relationship Matchups

Unity Biotechnology fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	156.3M	124.7M	124.4M	65.7M	59.1M	100.2M
Other Current Liab	7.4M	7.0M	5.3M	3.0M	2.7M	2.6M
Total Current Liabilities	14.5M	16.6M	19.6M	7.8M	9.0M	14.3M
Total Stockholder Equity	82.9M	59.6M	66.8M	28.4M	32.7M	31.0M
Net Tangible Assets	120.7M	82.9M	59.6M	66.8M	76.9M	57.5M
Property Plant And Equipment Net	36.1M	31.2M	26.9M	18.1M	20.8M	19.9M
Net Debt	41.2M	18.7M	34.6M	7.2M	8.3M	8.7M
Retained Earnings	(339.3M)	(400.0M)	(460.0M)	(484.4M)	(435.9M)	(457.7M)
Accounts Payable	2.6M	2.0M	1.8M	1.4M	1.2M	2.1M
Cash	17.8M	32.9M	12.7M	19.8M	17.8M	23.3M
Non Current Assets Total	55.5M	34.2M	27.8M	19.1M	21.9M	25.2M
Non Currrent Assets Other	1.4M	987K	52K	1.0M	919.8K	981.1K
Other Assets	2.1M	1.4M	987K	948K	853.2K	992.6K
Cash And Short Term Investments	97.7M	88.1M	94.8M	43.2M	38.9M	36.9M
Common Stock Shares Outstanding	5.1M	5.6M	9.5M	14.8M	17.0M	17.8M
Short Term Investments	79.9M	55.2M	82.1M	23.4M	21.1M	20.0M
Liabilities And Stockholders Equity	156.3M	124.7M	124.4M	65.7M	59.1M	100.2M
Non Current Liabilities Total	59.0M	48.5M	37.9M	29.5M	26.5M	33.0M
Capital Surpluse	324.7M	366.7M	422.4M	527.0M	606.1M	636.4M
Other Current Assets	6.3M	2.4M	1.5M	1.8M	1.6M	2.1M
Other Stockholder Equity	422.2M	459.6M	500.8M	512.8M	589.7M	355.1M
Total Liab	73.4M	65.1M	57.5M	37.3M	33.6M	43.4M
Property Plant And Equipment Gross	12.6M	31.2M	26.9M	27.3M	31.4M	17.9M
Total Current Assets	100.9M	90.5M	96.5M	46.6M	41.9M	81.9M
Accumulated Other Comprehensive Income	5K	(44K)	(251K)	(24K)	(27.6K)	(29.0K)
Property Plant Equipment	16.6M	36.1M	31.2M	7.8M	9.0M	16.9M
Net Invested Capital	107.4M	81.0M	87.2M	28.4M	25.6M	24.3M
Net Working Capital	86.4M	73.9M	76.9M	38.8M	34.9M	33.1M
Short Long Term Debt Total	59.0M	51.6M	47.4M	27.0M	31.0M	33.9M
Short Term Debt	4.5M	7.4M	12.6M	3.5M	4.0M	6.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

Additional Tools for Unity Stock Analysis

When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Unity Depreciation vs Free Cash Flow Analysis

Depreciation vs Free Cash Flow

Depreciation vs Free Cash Flow Correlation Analysis

Correlation Coefficient

Depreciation

Free Cash Flow

Unity Biotechnology fundamental ratios Correlations

Unity Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Unity Biotechnology fundamental ratios Accounts

Also Currently Popular

Additional Tools for Unity Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Non Current Liabilities Total
Non Current Assets Total	+ 0.97	Property Plant And Equipment Net
Non Current Liabilities Total	+ 0.96	Cash
Property Plant And Equipment Gross	+ 0.96	Other Stockholder Equity
Accounts Payable	+ 0.95	Other Current Liab
Total Liab	+ 0.95	Cash

Capital Surpluse	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.96	Retained Earnings
Preferred Stock Total Equity	- 0.95	Cash
Property Plant And Equipment Gross	- 0.94	Retained Earnings
Cash	- 0.94	Net Debt
Preferred Stock Total Equity	- 0.93	Total Liab